0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant

NCT ID: NCT02186132

Last Updated: 2014-07-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2013-02-28

Brief Summary

Balanced general anesthesia with neuromuscular blocking agents has been widely used for surgery.. At the end of surgery, neostigmine has been given for the reversal of neuromuscular blocking agents with several adverse effects such as bradycardia and profuse secretion. Atropine has been used to prevent those side effects of neostigmine. The routine dosages of the two drugs are 2.5 mg of neostigmine and 1.2 mg of atropine.

Tribuddharat S ey al. (1) has demonstrated that after giving 0.9 mg atropine together with 2.5 mg of neostigmine the mean heart rate during 1-8 minutes after the administration was increase 2-26 beats/min (bpm). At 9 and 10 minutes after administration of the drugs, the mean heart rate were decrease 0.9 and 1.6 bpm In the control group which receiving 1.2 mg of atropine, the mean heart rate during 1-10 minutes after administration was increase 4-32 bpm. However this study did not report the incidence of bradycardia and blood pressure. The mean heart rate prior to atropine and neostigmine was 74.43 + 11.82 bpm.(1)

Salem MG et al. (2) has demonstrated that after receiving 1.2 mg of atropine and 5 mg of neostigmine the mean heart rate during 2-110 minutes was decrease 5-29 bpm with the lowest heart rate at 40 minutes after administration. This study also did not report the blood pressure.

The baseline heart rate (HR) before administration of the reversal was associated with the following heart rate. Heinonen J et al. (3) has demonstrated that 80% of the patients after receiving 0.015 mg/kg of atropine 3 minutes before 0.03 mg of neostigmine for the reversal of pancuronium experienced bradycardia (heart rate < 50 bpm) compared with none in patients receiving alcuronium. However, before administration of atropine and neostigmine, the mean heart rate of patients was significantly lower in the pancuronium group.

Either tachycardia or bradycardia with hypotension causes adverse affect to patient especially in specific group like patient with coronary artery disease or undergoing craniotomy.

The primary objective of our study is to demonstrate the effect on heart rate (HR) and blood pressure of 0.6 mg atropine and 2.5 mg neostigmine for the reversal of muscle relaxant compare to 1.2 mg atropine.

Conditions

Bradycardia; Neostigmine Adverse Reaction; Adverse Reaction to Belladonna or Atropine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Atropine 0.6 mg

Atropine 0.6 mg intravenous

Group Type: EXPERIMENTAL

Atropine 0.6 mg

Intervention Type: DRUG

Atropine 0.6 mg intravenous

Atropine 1.2 mg intravenous

Atropine 1.2 mg intravenous

Group Type: ACTIVE_COMPARATOR

Atropine 1.2 mg

Intervention Type: DRUG

Atropine 1.2 mg intravenous

Interventions

Atropine 0.6 mg

Atropine 0.6 mg intravenous

Intervention Type: DRUG

Atropine 1.2 mg

Atropine 1.2 mg intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• ASA physical status 1-3
• age = or > 18 years
• patient receiving neuromuscular blocking agent

Exclusion Criteria

• baseline heart rate before administration of the study drugs < 65 bpm
• history of allergy to the study drugs
• patient receiving either of the following drugs include beta-blockers, calcium channel blocker, amiodarone or digoxin
• history of complete heart block or second degree AV block.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mahidol University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sirilak Suksompong, MD

Role: PRINCIPAL_INVESTIGATOR

Mahidol University

Other Identifiers

Si158/2012

Identifier Type: -

Identifier Source: org_study_id